BAP1 and nonpapillary renal cell carcinoma: Using a more clinically relevant organoid model derived from UM and ccRCC tumors, we observed significant synergy with the combination of dasatinib and SW076956, as well as saracatinib and SW063058, in BAP1-deficient PDTOs but not in wild-type ones.